The 2027 GOLD report is here — and it's reshaping how we think about COPD

The 2027 GOLD report is rolling out significant updates to COPD diagnosis and management, presented at the 2026 GOLD International COPD Conference in Philadelphia. One of the biggest shifts: CT scans should now be considered as part of the initial evaluation for all COPD patients (at least once, where available) — a notable expansion from the previous report, which limited CT use to differential diagnosis, lung volume reduction, and lung cancer screening. Mucus plugging, now recognized as a key driver of mortality and lung function decline, is newly highlighted under CT indications.

On the treatment front, the initial pharmacological recommendation for GOLD group A patients has been upgraded from a general bronchodilator to a long-acting muscarinic antagonist (LAMA), driven largely by tiotropium trial data. Non-pharmacological treatment also gets a major overhaul, with five new figures emphasizing pulmonary rehabilitation as "essential" — and a pointed reminder that it's being widely neglected in practice.

Key Takeaways:

• CT is now recommended at least once for all COPD patients as part of initial evaluation, with mucus plugging newly flagged as a clinical concern
• GOLD group A initial treatment shifts from bronchodilator → LAMA
• Cardiovascular comorbidities (hypertension, heart failure, CAD, arrhythmias) get more specific, actionable guidance — including that beta-blockers are not contraindicated in COPD patients with atrial fibrillation
• A new joint section with GINA addresses seven shared global challenges for COPD and asthma, including inhaler affordability and climate change

Why it matters: The GOLD report is the global standard for COPD care, and these updates will directly influence clinical practice worldwide. From expanding CT's diagnostic role to elevating pulmonary rehab and refining CVD management, the 2027 edition pushes for earlier, more personalized, and more comprehensive COPD care.